Broad Neutralization of Influenza B Hemagglutinin Antibodies via Receptor Mimicry
A study published in the Proceedings of the National Academy of Sciences (PNAS) in May 2026 details a significant breakthrough in understanding and combating Influenza B viruses. The research highlights that Influenza B infections cause seasonal flu with severity and hospitalization rates comparable to Influenza A, yet often receive less attention in vaccine development. The core finding involves the isolation of a panel of broadly neutralizing antibodies capable of targeting diverse Influenza B strains. These antibodies function through a unique mechanism involving receptor mimicry and specific glycan engagement on the viral hemagglutinin protein. By mimicking the host cell receptors that the virus typically binds to, these antibodies effectively block viral entry and neutralize the infection across various strains. This discovery offers promising implications for the development of universal flu vaccines or more effective therapeutic antibodies that can provide broad protection against evolving Influenza B lineages. The study underscores the critical need for continued research into Influenza B due to its substantial public health burden, aiming to reduce illness severity and healthcare costs associated with seasonal flu outbreaks globally.
Wire timeline
Broad Neutralization of Influenza B Hemagglutinin Antibodies via Receptor Mimicry
A study published in the Proceedings of the National Academy of Sciences (PNAS) in May 2026 details a significant breakthrough in understanding and combating Influenza B viruses. The research highlights that Influenza B infections cause seasonal flu with severity and hospitalization rates comparable to Influenza A, yet often receive less attention in vaccine development. The core finding involves the isolation of a panel of broadly neutralizing antibodies capable of targeting diverse Influenza B strains. These antibodies function through a unique mechanism involving receptor mimicry and specific glycan engagement on the viral hemagglutinin protein. By mimicking the host cell receptors that the virus typically binds to, these antibodies effectively block viral entry and neutralize the infection across various strains. This discovery offers promising implications for the development of universal flu vaccines or more effective therapeutic antibodies that can provide broad protection against evolving Influenza B lineages. The study underscores the critical need for continued research into Influenza B due to its substantial public health burden, aiming to reduce illness severity and healthcare costs associated with seasonal flu outbreaks globally.
Proceedings of the National Academy of Sciences: Proceedings of the National Academy of Sciences: Table of Contents